Xelari Inc.

Xelari's AI-powered platform transforms how molecular binders are designed, addressing critical limitations in biotechnology. Our XELAMERs (DNA/RNA-based functional molecular binders) surpass antibodies and aptamers in all key performance metrics, revolutionizing molecular binding technology. The Problem While 80% of biotech companies rely on antibodies for R&D: - Antibody discovery takes over a year and costs hundreds of thousands - Production requires months with cold-chain logistics - Aptamers have only 30% success rate Our Solution: XELAMERs - 24-hour design time versus 6-12 months for antibodies - Thousands of times more cost-efficient - Multi-functional: Each XELAMER can perform up to 5 distinct functions Contact: info@xelari.com | www.xelari.com